Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC.
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.
Faris
Jason E
JE
Massachusetts General Hospital Cancer Center, The Claire and John Bertucci Center for Genitourinary Cancers, 55 Fruit Street, Boston, MA 02114, USA.
Michaelson
M Dror
MD